Clinical Trial Update: Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial update reports on neoadjuvant Pyrotinib for hormone-receptor-positive, HER2-low high-risk early breast cancer, with the trial currently not recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Low Breast Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING